Intraosseous Cefuroxime Outperforms IV Dosing in Robotic Knee Surgery Trial
Intraosseous Cefuroxime Outperforms IV Dosing in Robotic Knee Surgery Trial
A randomized controlled trial found that injecting cefuroxime directly into bone before robotic-assisted total knee replacement results in significantly higher tissue concentrations of the antibiotic compared to intravenous administration. The study, published in Arthroplasty, showed that a 750 mg intraosseous dose achieved nearly as high tissue concentrations as a 1,500 mg dose while maintaining lower systemic levels. The results suggest that intraosseous administration may be more effective for prophylactic antibiotic delivery in robotic knee surgery.
Full article
Article text is not available for this item. Read it at the original source.
Read full article at sourcebioengineer.org · Opens in a new tab; source language may differ.
This study demonstrates that intraosseous cefuroxime administration in robotic knee surgery achieves significantly higher local tissue concentrations compared to intravenous dosing, with potential benefits for infection prevention. The findings suggest that lower intraosseous doses may be sufficient, reducing systemic exposure and antibiotic use.
What the source reports
Publisher-reported claims, with original evidence. These results have not been independently verified by RoboSignal.
Reported numbers
tissue concentrations
16
View original evidence
The team also prespecified an exploratory tissue-concentration benchmark of 16 micrograms per gram, numerically four times the epidemiological cutoff value of 4 micrograms per milliliter for Staphylococcus aureus in the EUCAST database. Because the reference value is a fluid concentration while tissue measurements are expressed per gram of tissue, the researchers stressed that the benchmark should be regarded as an
Open source S15tissue concentrations
4
View original evidence
The team also prespecified an exploratory tissue-concentration benchmark of 16 micrograms per gram, numerically four times the epidemiological cutoff value of 4 micrograms per milliliter for Staphylococcus aureus in the EUCAST database. Because the reference value is a fluid concentration while tissue measurements are expressed per gram of tissue, the researchers stressed that the benchmark should be regarded as an
Open source S15tissue concentrations
9–13
View original evidence
traosseous group and 99.1 percent in the 1,500 milligram intraosseous group reached that level. Compared with intravenous administration, the 750 milligram intraosseous regimen produced fat concentrations 9 to 13 times higher, synovial concentrations 4 to 8 times higher, and bone concentrations 9 to 41 times higher, with the 1,500 milligram intraosseous dose producing even higher tissue levels. The two earliest tissu
Open source S17
- paper: not_reported
Source excerpts and review record
Automatically extracted; no manual editorial approval recorded.
The team also prespecified an exploratory tissue-concentration benchmark of 16 micrograms per gram, numerically four times the epidemiological cutoff value of 4 micrograms per milliliter for Staphylococcus aureus in the EUCAST database. Because the reference value is a fluid concentration while tissue measurements are expressed per gram of tissue, the researchers stressed that the benchmark should be regarded as an
Open source S15
operational yardstick rather than a strict pharmacokinetic equivalence. The results were striking. Cefuroxime concentrations in all fat, synovium and bone samples were significantly higher in both intraosseous groups than in the intravenous group. In the intravenous group, 59.3 percent of tissue samples, 64 of 108, fell below the 16 microgram per gram benchmark, whereas 95.7 percent of samples in the 750 milligram in
Open source S16
traosseous group and 99.1 percent in the 1,500 milligram intraosseous group reached that level. Compared with intravenous administration, the 750 milligram intraosseous regimen produced fat concentrations 9 to 13 times higher, synovial concentrations 4 to 8 times higher, and bone concentrations 9 to 41 times higher, with the 1,500 milligram intraosseous dose producing even higher tissue levels. The two earliest tissu
Open source S17
Source：Surgical robotics — News discovery · bioengineer.org